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Abstract
Background: Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent
epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa),
elevated expression of miR-30d that targets SOCS1 mRNA is associated with increased risk of disease recurrence.
SOCS1 can mediate its tumor suppressor functions by diverse mechanisms such as inhibiting the JAK-STAT
signaling pathway, promoting the tumor suppressor functions of p53, attenuating MET receptor tyrosine kinase
signaling and blocking the oncogenic potential of the cell cycle inhibitor p21CIP1 (p21). Here, we studied the
expression of SOCS1 and the downstream targets of its putative tumor suppressor functions (p53, MET and p21) in
human PCa specimens to evaluate their significance as markers of disease prognosis.
Methods: Tissue microarrays were constructed of 78 archived prostatectomy specimens that were grouped
according to the recommendations of the International Society of Urological Pathology (ISUP) based on the
Gleason patterns. SOCS1, p53, MET and p21 protein expression were evaluated by immunohistochemical staining
alongside the common prostate cancer-related markers Ki67, prostein and androgen receptor. Statistical correlations
between the staining intensities of these markers and ISUP grade groups, local invasion or lymph node metastasis
were evaluated.
Results: SOCS1 showed diffuse staining in the prostatic epithelium. SOCS1 staining intensity correlated inversely
with the ISUP grade groups (ρ = −0.4687, p <0.0001) and Ki67 (ρ = −0.2444, p = 0.031), and positively with prostein
(ρ = 0.3511, p = 0.0016). Changes in SOCS1 levels did not significantly associate with those of p53, MET or p21.
However, p21 positively correlated with androgen receptor expression (ρ = −0.1388, p = 0.0003). A subset of patients
with regional lymph node metastasis, although small in number, showed reduced SOCS1 expression and increased
expression of MET and p21.
Conclusions: Our findings suggest that evaluating SOCS1 and p21 protein expression in prostatectomy specimens
may have a prognostic value in identifying the aggressive disease. Hence, prospective studies with larger numbers
of metastatic PCa specimens incorporating clinical correlates such as disease-free and overall survival are warranted.
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Background
Prostate cancer (PCa) is the second most common cancer
and fifth leading cause of cancer-associated mortality in
men, with an estimated number of 1.1 million cases
worldwide [1]. Despite early detection and treatment
involving radical prostatectomy, radiotherapy and/or
androgen deprivation, PCa continues to be a major cause
of cancer-associated morbidity and mortality. Develop-
ment of resistance to androgen deprivation therapy and
acquisition of metastatic potential are the major causes of
PCa mortality [2]. Cellular and animal models of PCa have
elucidated many signaling pathways that render PCa
refractory to treatment and contribute to metastatic dis-
semination [3, 4]. This knowledge can be exploited not
only to develop personalized therapies for the recalcitrant
disease but also to the development and testing of bio-
markers for early detection of the aggressive disease.
The suppressor of cytokine signaling 1 (SOCS1) protein
is considered a tumor suppressor because of frequent
repression of the SOCS1 gene promoter by CpG methyla-
tion in many types of cancers including hepatocellular car-
cinoma, leukemia and pancreatic adenocarcinoma [5–9].
SOCS1 expression is also inhibited by microRNAs such as
miR-19 and miR-155 in human cancers [10–12]. SOCS1 is
one of the genes that are under-expressed in the
androgen-independent PCa cell line LNCaP-C81 com-
pared to the androgen-dependent LNCaP-33 cell line [13].
Even though methylation of the SOCS1 promoter occurs
only in 20% of PCa cases, increased expression of the
SOCS1-targeting micro-RNA, miR-30d, has been reported
to occur frequently in PCa [14, 15]. In fact, elevated miR-
30d expression in PCa specimens correlates with early
biochemical recurrence, supporting a tumor suppressor
role for SOCS1 in PCa [15]. A number of studies have
shown that SOCS1 attenuates growth of prostate cancer
cells in vitro and in vivo [16–18].
The SOCS1 gene is induced by diverse cytokines and
growth factors, and inhibits their signaling in a negative
feedback manner [8, 19]. SOCS1 has been shown to in-
hibit IL-6 and hepatocyte growth factor (HGF) signaling,
which are implicated in PCa pathogenesis [16–18].
SOCS1 can exert its anti-tumor functions through
diverse mechanisms. SOCS1 contains a central SH2
domain and C-terminal SOCS box. The SH2 domain
binds to JAK kinases activated by cytokines and growth
factor receptor tyrosine kinases (RTK), and thus blocks
downstream signaling events [8, 19]. The SOCS box me-
diates ubiquitination of SOCS1-bound proteins, thereby
promoting their degradation by proteasomes. We have
shown that SOCS1 regulates HGF signaling by promot-
ing ubiquitination and proteasomal degradation of the
MET RTK [20, 21]. In cellular systems, SOCS1 co-
operates with p53 to enforce oncogene-induced senes-
cence [22]. However, in a mouse model of hepatocellular
carcinoma, SOCS1 deficiency is associated with increased
expression of a p53 target gene, the cyclin-dependent
kinase inhibitor p21CIP1/WAF1 (p21) [23]. Even though p21
generally functions as a tumor suppressor, its cytosolic
localization may promote tumor growth [24, 25]. Indeed,
overexpression of p21 occurs in several human cancers
and correlates with poor prognosis [24]. The relative con-
tribution of the different downstream targets of SOCS1 in
mediating tumor suppression in diverse cancers has not
been studied yet. In PCa, even though p53 mutation is un-
common, MET and p21 are implicated in disease progres-
sion. Expression of MET occurs in 40% of localized PCa
and correlates with Gleason score and lymph node metas-
tasis, reaching nearly 100% in bone metastases [26–29].
Similarly, increased expression of p21 mRNA and protein
in PCa has been associated with progression to androgen-
independent cancer and resistance to apoptosis induction
by chemotherapeutic agents [30, 31].
In this study, we investigated SOCS1 protein expres-
sion in prostatectomy specimens and its correlation to
disease severity, with the goal of testing its utility as a
prognostic biomarker. We examined the correlation
between SOCS1 expression to those of its putative
downstream targets of tumor suppression namely, p53,
MET and p21 [21–23]. We observed significant inverse
correlation between SOCS1 expression and disease
severity. However, SOCS1 expression did not correlate
with that of p53, MET or p21 in the whole study cohort.
Within the study population, cases with regional lymph
node metastasis, albeit small in number, showed de-
creased SOCS1 and increased MET and p21 expression.
Methods
Human prostatectomy specimens
From archived radical prostatectomy specimens received
at the pathology department of the Centre hospitalier
universitaire de Sherbrooke (CHUS), 175 consecutive
samples collected between 2012 and 2015 were selected
for this study. As the priority of this study was to evalu-
ate tissue protein expression, and because archived spec-
imens progressively lose antigenicity, only recent
prostatectomy specimens collected between 2012 and
2015 were used. All the prostatectomy specimens were
treatment-naïve. The study design also did not include
serum PSA, disease outcome or patient follow-up, as
only the recent prostatectomy specimens were priori-
tized to assess marker expression. Following approval by
the Ethics committee of the Centre de Recherche du
CHUS (Project #2014-734, 13–222), the patients or their
families were contacted and consent was obtained from
90 patients. Among them, 12 cases were excluded due to
a small tumor size of less than 5 mm in diameter, and
78 were included in this study.
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Tumor grading and classification
Tumor grading and staging data from the histopathology
report were verified. Tumors were re-categorized
according to the recommendations of the International
Society of Urological Pathology (ISUP) into 5 groups,
represented by the sum value of the first and second
most prevalent Gleason patterns [32]: group 1 (Gleason
score ≤6), group 2 (Gleason score 7 = 3 + 4), group 3
(Gleason score 7 = 4 + 3), group 4 (Gleason scores 8 = 4
+ 4, 3 + 5, 5 + 3) and group 5 (Gleason score 9–10) [33].
All 78 cases harboured prostatic acinar adenocarcinoma.
Among them, four showed foamy gland features, one
displayed mucinous features and two others contained a
ductal adenocarcinoma component. Within the study
population, lymph node dissection had been performed
in 36 cases, of which only 4 (N1) showed lymph node
metastasis and the rest (N0, n = 32) did not. The speci-
mens were categorized into two additional groups T2
and T3 stages, respectively representing those with car-
cinoma confined within the prostatic capsule (organ
confined) and those that have breached this confinement
(extra-prostatic extension) according to the American
Joint Committee on Cancer (AJCC) Staging manual (7th
edition) [34].
Construction of tissue microarray (TMA)
Following a thorough review of the haematoxylin and
eosin (H&E)-stained slides, the largest tumor foci repre-
sentative of the Gleason score was identified and corres-
pondingly mapped on the paraffin block using a
stereomicroscope (SZ51, Olympus) for precise targeting
with the TMA MASTER system (3DHISTECH Ltd,
Budapest, Hungary). The areas rich in tumor cells and
representing the two prominent Gleason patterns were
targeted. One large 2 mm diameter core was extracted
from the mapped area and the 78 tumor cores were fit-
ted in three TMAs using the TMA MASTER system.
Cores containing clearly defined transitional epithelium,
normal prostatic epithelium, low-grade and high-grade
prostatic intraepithelial neoplasia (PIN) served as control
or reference. PIN was defined according to WHO
criteria [33].
Immunohistochemistry
TMA sections of 4 μm thickness mounted on charged
slides were deparaffinised, re-hydrated and heat-induced
antigen retrieval was performed on DAKO PT Link pre-
treatment module (Dako Pathology products, Missis-
sauga, ON) using low or high pH Envision FLEX Target
Retrieval Solutions (Dako). Subsequent steps were
carried out on DAKO Autostainer Link. Endogenous
peroxidase activity was blocked using Envision FLEX
Peroxidase-blocking Reagent, followed by incubation
with the primary antibodies (Ab) listed in Table 1. The
EnVision FLEX /HRP (Dako) reagent containing a
dextran polymer conjugated to anti-mouse Ig and anti-
rabbit Ig and HRP was used as the secondary Ab. All
washing steps were carried out using the Envision FLEX
wash buffer and positive staining was detected by pre-
cipitation of diaminobenzidine (DAB) using the Envision
FLEX DAB+ reagent. Slides were counterstained with
hematoxylin, and coverslips were mounted using the
Faramount mounting medium (Dako). The images were
captured using an automated slide scanner (Aperio
ScanScope XT, Aperio, Vista, California), analysed and
scored in a blinded manner. A semi-objective scoring
method (H-score) was used to quantify the staining. H-
Score was evaluated on the whole tissue core. For the
various markers, only the nuclear (Ki67, p53, AR and
p21), the granular cytoplasmic (Prostein, SOCS1) or the
membrane (MET) staining was considered for scoring.
The staining intensities were graded on the scale of 0,
1, 2 and 3, representing absent, weak, moderate and
strong staining. These values were multiplied by the
respective percentage of staining to obtain the H-scores
ranging from 0 to 300. Thus, the H-score recognises
broad ranges of antigen expression and avoids arbitrary
cut-offs.
Statistical analysis
Statistical analyses were carried out using the GraphPad
Prism 6 software (GraphPad Software, San Diego, USA).
The data points were tested for Gaussian distribution
before performing relevant statistical analyses, as indi-
cated in each figure. For each dataset within groups, the
distribution, mean and standard deviation within the
95% confidence limits are shown. Correlation between
any two parameters was evaluated by non-parametric
Spearman correlation test and the correlation coefficient
(ρ) and the p value of the correlation are indicated
within each figure. The slope was generated by non-
linear regression curve-fit analysis. Non-parametric
Kruskal-Wallis and Mann–Whitney tests were employed
for comparing multiple or two groups, respectively.
Statistically significant p values are represented by aster-
isks (* ≤ 0.05, ** ≤ 0.01), or the actual values are indicated
within each figure.
Results
Ki67 and prostein expression in PCa correlates with
tumor grade in the study cohort
In order to evaluate the protein expression of SOCS1
and its putative downstream targets of tumor suppres-
sion in PCa, we constructed TMAs from archived PCa
specimens and performed automated IHC staining to
ensure staining homogeneity. To limit overlooking po-
tential heterogeneity within individual tumor specimens,
precautions were taken to include as much high-grade
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tumor foci as possible within the TMA core and not to
exclude any smaller foci of higher grade. The TMAs
were first stained by H&E to ascertain their histological
features and distinguish carcinoma, PIN and benign
structures, allowing their classification into five ISUP-
recommended groups: 1 (n = 16), 2 (n = 39), 3 (n = 1), 4
(n = 8) and 5 (n = 4). The TMA sections were then
stained for Ki67, a common cancer-associated marker
(Fig. 1b). The high-grade tumors contained many Ki67+
cells compared to intermediate grade tumors, low grade
tumors showed occasional Ki67+ cells, and the normal
tissue rarely showed any positivity. Staining for prostein
showed an opposite pattern compared to Ki67 staining.
In general, low-grade tumors displayed intense prostein
staining comparable to normal prostatic epithelium, and
high-grade tumors showed reduced prostein staining
(Fig. 1c). Consistent with these staining patterns, regres-
sion analysis showed highly significant positive correl-
ation between the tumor grade and Ki67 staining,
whereas prostein showed an inverse correlation (Fig. 1d
and e). These results indicated that the study cohort was
well represented by samples of different disease severity,
despite containing relatively fewer high-grade tumors.
SOCS1 staining decreases with disease severity
It has been reported that androgen stimulation induces
SOCS1 gene expression in PC3 cells [17]. Therefore, we
evaluated the expression of androgen receptor (AR) and
SOCS1 in PCa TMAs. The representative staining pat-
terns and the corresponding tumor grades are shown in
Fig. 2a and b. In contrast to antibodies specific to Ki67,
prostein and AR that are approved for pathological diag-
nosis, the SOCS1 Ab is a research-grade rabbit poly-
clonal Ab from Santa Cruz Biotechnology (H-93,
Catalogue #sc-9021). This SOCS1 Ab has been previ-
ously used on gastric and PCa specimens [17, 35] and by
the Human Protein Atlas project [36]. This Ab detected
a specific band of 27 kDa as expected in western blot
analysis of COS-7 cells expressing human SOCS1 pro-
tein (Additional file 1: Figure S1). Two additional bands
of higher MW estimated at 42 and 50 kDa were also
observed only in SOCS1-transfected cells, suggesting
that these bands might represent post-translationally
modified SOCS1 protein. None of these bands were
detected in control vector-transfected cells, indicating
the specificity of the SOCS1 Ab used. We have opti-
mized the staining conditions for IHC using this Ab,
specifically pH of the antigen retrieval solution, pri-
mary Ab dilution and incubation time, using human
fallopian tube specimens as documented in the manu-
facturer’s datasheet (data not shown). We obtained
specific SOCS1 staining in PCa specimens as indi-
cated by positive and negative cells within the same
field of observation (Fig. 2b). We observed that
SOCS1 showed a granular cytoplasmic staining of the
prostatic epithelium with intense staining at the peri-
nuclear region, predominantly on the luminal side
(Fig. 2c). Whereas AR staining did not correlate with
the ISUP grade groups, SOCS1 staining showed a sig-
nificant negative correlation, similarly to prostein
(Fig. 2d and Fig. 1e).
Although SOCS1 showed a staining pattern similar to
that of prostein (Fig. 1c and Fig. 2b), it was unlikely that
SOCS1 Ab displayed any cross-reactivity with prostein
for the following reasons. While the prostein staining is
highly specific to the prostatic epithelium and carcinoma
as expected [37], the SOCS1 Ab also stained immune
and stromal cells surrounding the gland and around the
prostatic ducts (Fig. 2e and f). Moreover, in contrast to
prostate epithelial cells, SOCS1 staining in immune cells
showed a predominant nuclear distribution (Fig. 2e-g),
indicating that SOCS1 staining is distinct from that of
prostein.
Evaluation of the relationship between SOCS1 stain-
ing and that of AR did not show any association,
whereas a positive correlation was observed between
SOCS1 and prostein (Fig. 3a). However, AR staining
correlated positively with Ki67 staining, whereas
SOCS1 and prostein displayed significant negative cor-
relation with Ki67 staining (Fig. 3b), suggesting that
SOCS1 expression in PCa specimens might have a diag-
nostic significance.
Table 1 Antibodies used in this study
Ab Source Clone Cat# Dilution Incubation time (min) pH
AR DAKO, Mouse mAb AR441 M3562 1/25 20 9.0
Ki67 DAKO Mouse mAb MIB-1 GA626 RTU 20 6.1
p21 DAKO, Mouse mAb SX118 M7202 1/50 20 9.0
p53 DAKO, Mouse mAb DO-7 GA616 RTU 20 9.0
Prostein DAKO, Mouse mAb 10E3 IR088 RTU 20 9.0
MET CST Rabbit mAb D1C2 #8198 1/300 40 9.0
SOCS1 SCB Rabbit polyclonal Ab – H-93 1/150 100 9.0
(sc-9021)
RTU Ready-To-Use dilution, CST Cell Signaling Technology, SCB Santa Cruz Biotechnology
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Relationship between SOCS1 expression and the putative
downstream targets of its tumor suppressor functions
SOCS1 can mediate tumor suppression by several poten-
tial mechanisms that were defined using cell and animal
models. These include activation of p53-induced cellular
senescence, and inhibition of oncogenic MET and p21
signalling through their ubiquitination and proteasomal
degradation [20–23]. Hence, we postulated that the loss
of SOCS1 might result in efficient p53 activation and
compensatory upregulation of p53 expression, and
increase in the expression of MET and p21. As each of
these proteins is implicated in PCa pathogenesis [29, 30,
38], we evaluated their expression and correlation to
SOCS1 levels in PCa TMAs. Representative expression
patterns of p53, MET and p21 are shown in Fig. 4a-c.
Occasionally, MET expression was confined to cyst-like
Fig. 1 Ki67 and prostein staining in PCa specimens correlate with tumor grade. a Histopathological features of normal prostatic epithelium and
representative ISUP grade groups of PCa specimens, as revealed by H&E staining. The Gleason scores corresponding to the ISUP grade group is
given within parenthesis. b, c Representative immunohistochemical staining intensities of Ki67 and prostein in normal prostatic epithelium and in
PCa specimens. The H-score of IHC staining intensity is indicated at the top of each specimen, and the ISUP grade groups with the Gleason scores
in parenthesis at the bottom. Two specimens from group 2 are presented to illustrate the variation in staining intensity within groups. d, e Distribution
of the H-scores of Ki67 (d) and prostein (e) across the ISUP grade groups. The slope represents the correlation between the H-score and the ISUP grade
groups. Spearman’s rank correlation coefficient (ρ) and its statistical significance (p) are indicated. Statistical analyses between grade groups were
carried out using one-way ANOVA adjusted with Kruskal-Wallis multiple comparisons test, and the significant p values are indicated
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structures and atrophic ducts with true membranous
staining (Fig. 4d), although its significance is unclear.
While p53 expression showed significant positive correl-
ation with ISUP grade groups, MET and p21 only
showed a tendency for positive correlation that were not
statistically significant (Fig. 4e). SOCS1 staining did not
correlate with the expression of p53, MET or p21
(Fig. 4f ). These results suggested that the loss of SOCS1
Fig. 2 SOCS1 expression in PCa correlates inversely with the tumor grade. a, b Representative immunohistochemical staining intensities of
androgen receptor (AR) and SOCS1 in normal prostatic epithelium and representative PCa specimens. The H-score of IHC staining intensity and
the ISUP grade groups are indicated for each specimen. Two specimens from group 2 are presented to illustrate the variation in staining intensity
within groups. c High power image of SOCS1 staining in normal prostatic epithelium. d Distribution of the H-scores of AR and SOCS1 across the
ISUP grade groups. The slope shows the correlation between the H-score and the ISUP grade groups. Spearman’s rank correlation coefficient (ρ)
and its statistical significance (p) are indicated. Statistical analyses between grade groups were carried out using one-way ANOVA adjusted with
Kruskal-Wallis multiple comparisons test, and no significant differences were found. e-g Distinct staining patterns of prostein and SOCS1 in the
prostate parenchyma (e) and at the prostate-urethra junction (f). Note the SOCS1 staining of adjacent immune cells (arrows) and stromal cells
(arrowheads). g High power image of SOCS1 staining in lymphocytes within the prostatic stroma showing distinct nuclear positivity
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might affect the downstream mediators of its tumor sup-
pression mechanisms in a heterogeneous manner.
Expression of p21 strongly correlates with AR levels
It has been reported that AR signalling represses MET
expression, whereas androgen deprivation is associated
with increased expression of p21 [30, 39], suggesting
that escape to androgen independence would lead to
increased expression of MET and p21, promoting their
oncogenic functions. Therefore, we examined the rela-
tionship between the expression of AR and those of
MET and p21. A strong positive association was
observed between AR and p21 expression, whereas the
positive correlation tendency between AR and MET was
not statistically significant (Fig. 5a). MET and p21, which
showed a significant positive correlation were also
strongly associated with Ki67 staining (Fig. 5b and c).
These results indicated that even though AR expression
did not correlate with the ISUP grade or MET (Fig. 2d),
AR and MET signalling might influence the expression
of p21 expression and its oncogenic functions.
Expression of SOCS1 and its downstream targets in locally-
advanced and metastatic PCa
We grouped the specimens into tumors that are either
confined within (T2, n = 47) or spread beyond (T3, n =
41) the prostatic capsule. Evaluation of the marker
expression in these two groups revealed that the invasive
tumors showed significantly higher Ki67 and lower pros-
tein staining (Fig. 6). On the other hand, expression of
AR, SOCS1, p53, MET or p21 was not significantly dif-
ferent between T2 and T3 groups. A subset of the sam-
ples, for which tumor spread to the regional lymph node
had been evaluated (n = 36), were grouped into N0 (n =
32) and N1 (n = 4) subgroups, respectively representing
cases without or with metastatic spread to the regional
lymph node. Even though the latter group contained
only a limited number of cases, their Ki67 expression
was significantly higher and prostein levels were signifi-
cantly lower compared to specimens in the former
group, while the AR expression was comparable (Fig. 7).
Moreover, specimens from cases with lymph node me-
tastasis showed significantly reduced SOCS1 staining
and concomitant increase in MET and p21 expression.
Although these findings need to be confirmed in larger
study populations, they suggest that SOCS1, MET and
p21 levels could be useful as predictive markers of meta-
static PCa.
Discussion
Given that the expression of SOCS1 is regulated at post-
transcriptional level by microRNAs [10–12, 15], detec-
tion of SOCS1 protein in cancer tissues would represent
a direct approach to evaluate SOCS1 as a potential
Fig. 3 SOCS1 expression does not correlate with AR but correlates positively with prostein and negatively with Ki67 levels. a Correlation between the
H-scores of SOCS1 and that of AR or prostein. b Correlation between the H-scores of Ki67 and that of AR, prostein or SOCS1. The slope represents the
correlation between the H-scores. Spearman’s rank correlation coefficient (ρ) and its statistical significance (p) are indicated
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Fig. 4 Expression of p53, MET or p21 does not correlate with SOCS1 staining in PCa. Representative immunohistochemical staining intensities of
p53 (a), MET (b) and p21 (c) in normal prostatic epithelium and representative PCa specimens. The H-score of IHC staining intensity and the ISUP
grade groups are indicated for each specimen. d Occasional staining of cyst-like structures by the anti-MET antibody. e Distribution of the H-
scores of p53, MET and p21 across the ISUP grade groups. Slope represents the correlation between the H-score and the ISUP grade groups.
Statistical analyses between grade groups were carried out using one-way ANOVA adjusted with Kruskal-Wallis multiple comparisons test, and the
significant p values are indicated. f Correlation between the staining intensities of SOCS1 and that of p53, MET or p21. Spearman’s rank correlation
coefficient (ρ) and its statistical significance (p) are indicated for E and F
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cancer biomarker. However, detection of endogenous
SOCS1 protein has been particularly difficult for two
reasons. Firstly, the basal SOCS1 gene expression in nor-
mal tissues is very low; however, it is induced by myriad
of inflammatory cytokines, growth factors, chemokines
and other mediators such as prostaglandins and andro-
gens [17, 40–42]. Secondly, most available SOCS1
antibodies are not sensitive enough to detect the
endogenous SOCS1 protein. Hence, the literature on
SOCS1 expression is mostly restricted to quantification
of SOCS1 mRNA with only a few reports on SOCS1 pro-
tein expression [9, 17, 35, 43, 44]. Given that SOCS1
gene repression occurs in many cancers by diverse
mechanisms, clearly there is a need for developing and
testing more sensitive and specific SOCS1 antibodies for
diagnostic purpose in surgical pathology.
We observed different staining intensities of SOCS1 in
prostatectomy specimens that showed strong inverse
correlation with the ISUP grade groups and Ki67 stain-
ing. Moreover, tumors with regional lymph node in-
volvement showed significantly lower SOCS1 expression
compared to those without. These findings indicate that
SOCS1 expression is diminished during PCa progression
and support the potential tumor suppressor role of
SOCS1 in this cancer. Moreover, the finding that SOCS1
staining was reduced but not abolished in PCa
specimens is consistent with the earlier reports that
repression by CpG methylation occurs only in a small
subset of PCa, whereas the expression of the SOCS1-
targeting miR-30d is more frequent [14, 15]. Hence,
evaluating SOCS1 protein would be more informative
than quantifying CpG methylation of the SOCS1 gene,
SOCS1-targeting micro-RNA or SOCS1 mRNA levels.
In the current study, we examined how reduced ex-
pression of SOCS1 protein in PCa specimens impacted
on p53, MET and p21, which are regulated by SOCS1
[21–23] and are implicated in PCa progression [29, 30,
38]. In the PCa grade groups, we observed variable pro-
tein staining for p53, MET and p21, of which only p53
correlated with either disease severity, and none of them
correlated with SOCS1protein expression. Evaluation of
p53 in human cancers has restricted diagnostic/prognostic
utility because increased expression generally correlates
with mutated or dysfunctional p53 [45]. Nonetheless, we
postulated based on the requirement of SOCS1 to
mediate p53-dependent cellular senescence [22] that
SOCS1 deficiency might increase p53 expression,
similarly to inactivating p53 mutations. Likewise, we
expected increased protein levels of MET and p21 in
cases where SOCS1 was limiting, as the latter attenu-
ates MET signalling and p21 expression at least partly
via ubiquitination and proteasomal degradation [21,
Fig. 5 AR expression in PCa positively correlates with MET and p21 levels. Correlation between the staining intensities of (a) AR and p21 or MET, (b)
MET and p21, and (c) Ki67 and MET or p21 in PCA specimens. Spearman’s rank correlation coefficient (ρ) and its statistical significance (p) are indicated
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23]. Even though there was a tendency of inverse cor-
relation between SOCS1 and p53, MET or p21, they
were not statistically significant (Fig. 4f ). Clearly,
studies on larger cohorts are needed either to confirm
this tendency, or to support the alternate possibility
that the decrease in SOCS1 expression need not ne-
cessarily affect all of its downstream mediators of
tumor suppression, as the SOCS1-mediated suppres-
sion pathways may vary in individual cancers. Besides,
other molecules/pathways might influence the down-
stream mediators of SOCS1 to a variable extent in in-
dividual cancers.
Major prognostic determinants of PCa are grade, local
extension, lymphovascular invasion and lymph node
metastasis. Still, many intermediate grade carcinomas
extend outside the prostate gland or metastasize, and
many high-grade carcinomas are organ-confined at time
of surgery. In such situations, additional prognosis
markers would be important in determining whether
more aggressive treatment is warranted. A lot of effort
has been made in the last two decades to develop and
refine diagnostic and prognostic PCa biomarkers [46].
The former group (e.g., % of free PSA over total PSA,
PCA3/DD3 gene expression) strives to achieve higher
specificity than total serum PSA levels in order to over-
come false-positive results and avoid unnecessary biop-
sies. On the other hand, prognostic biomarkers such as
early PCa antigen-2 (EPCA-2) and post-operative PSA
velocity (PSAV) and doubling time (PSAD) have shown
promise in predicting PCa aggressiveness, risk of non-
organ confined disease and disease recurrence. SOCS1
immunostaining may complement the latter group in
Fig. 6 SOCS1 expression is not significantly different between organ-confined PCa and tumors with extra-prostatic extension. Tumors confined
within the prostatic capsule (T2, n = 47) and those that have spread beyond (T3, n = 31) were compared for the staining intensities of Ki67, AR,
prostein, SOCS1, p53, MET or p21. Median values with range (bars) are indicated. Nine samples that showed no MET expression (5 in T2, 4 in T3)
were not indicated due to log scale of the y-axis. The datasets were compared by Mann–Whitney test and statistically significant p values are
indicated in bold
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predicting aggressive disease, although further studies in
larger cohorts with non-organ confined disease and
metastatic PCa as well as development of refined
reagents with improved sensitivity and specificity are
needed.
Androgen receptor (AR) signalling is a major onco-
genic driver in PCa progression via induction of pro-
mitotic genes, and the AR gene is often amplified or
mutated in PCa that have become resistant to andro-
gen deprivation therapy [47]. PCa with acquired re-
sistance to therapy display distinct AR-responsive
gene expression signature [48]. In recent studies, the
AR splice variant AR-V7 has emerged as a predictive
biomarker of PCa responsiveness to next generation
androgen targeting therapies [49]. We observed that
AR expression did not vary significantly across the
PCa grades or the tumor stages T2 and T3. However,
a strong positive correlation was observed between
AR expression and Ki67 staining, in agreement with
the ability of AR signalling to stimulate cell prolifera-
tion [47]. Even though androgen stimulation induces
SOCS1 gene expression in PC3 cells [17], we did not
find significant correlation between AR and SOCS1
protein expression. Nonetheless, SOCS1 protein level
showed significant negative correlation with Ki67
staining, reflecting the loss of SOCS1-dependent con-
trol of other growth stimulatory pathways.
Tumors with regional lymph node metastasis, despite
being limited in number, showed significantly lower
SOCS1 and prostein expression and higher levels of
Ki67, MET and p21 than those without lymph node
involvement (Fig. 7). SOCS1 might impinge on multiple
signaling pathways that promote aggressive growth, mi-
gration, invasion and metastasis, resulting in metastatic
spread to regional lymph nodes. Increased MET expres-
sion had been reported in metastatic PCa [28]. We have
Fig. 7 Decreased expression of SOCS1 and increased expression of MET and p21 in PCa are associated with regional lymph node spread. Tumors
from PCa patients without lymph nodes metastasis (N0, n = 32) were compared to those with lymph node metastasis (N1, n = 4) for the staining
intensities of Ki67, AR, prostein, SOCS1, p53, MET or p21. Median values with range (bars) are indicated. The datasets were compared by Mann–
Whitney test. Statistically significant p values are indicated in bold
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recently shown using PCa cell lines that SOCS1 inhibits
HGF-induced MET signaling and attenuated their migra-
tion and invasion [18]. Consistent with this report, MET
overexpression correlated with high proliferation and
regional lymph node metastasis (Fig. 5 and Fig. 7). How-
ever, we did not observe significant correlation between
SOCS1 and MET protein expression. Several factors
could contribute to this discrepancy between the studies
on cell lines and in primary cancers. For instance, in
primary cancers retaining SOCS1 expression, MET
mutations might allow escape from SOCS1-mediated
regulation. Alternatively, signaling pathways other than
MET might contribute to aggressive growth of cancer
cells retaining SOCS1 expression. The association
between p21 and metastasis, but not with tumor grade is
also intriguing. Although the number of metastatic
cancers included in our study is small, our finding raises
the possibility that the proposed function of cytosolic
p21 in promoting cell motility [50] might contribute to
PCa metastasis.
Even though the loss of SOCS1 did not correlate with
increased MET or p21 expression as we had expected,
our findings support the tumor suppressor function of
SOCS1, and the oncogenic potential of MET and p21 in
PCa. The expression of p21 also showed a strong correl-
ation to AR levels, which is expressed in androgen-
independent PCa and contributes to disease progression
in a ligand-independent manner, renewing the interest
in AR blockade [51, 52]. MET and AR levels also showed
a marked tendency for positive correlation, although this
was not statistically significant. Overall, the expression
of SOCS1, MET and p21 in PCa specimens may be use-
ful to identify cases that are prone to metastatic spread
and thus to put them on more aggressive treatment and/
or under close monitoring. While highly specific, clinical
grade anti-p21 Abs are available from DAKO, anti-MET
Abs suitable for such use are still in development [53]
and efforts must be made to develop clinical grade
SOCS1 Abs.
Our study design did not include patient follow-up for
responsiveness to therapy or survival. Therefore, we
analyzed correlation between SOCS1 gene expression and
patient survival in datasets obtained from the cBioportal
(http://www.cbioportal.org/) [54] and PrognoScan (http://
www.abren.net/PrognoScan/) [55] cancer web portals. We
did not find any significant correlation between SOCS1
gene expression and patient survival in both datasets
(Additional file 2: Figure S2). The currently available public
cancer databases do not contain protein expression data.
Therefore, it is necessary to carry out prospective studies
on SOCS1 protein expression in PCa and other cancers
with a wider scope, including treatment responsiveness,
disease-free survival and overall survival. The present study
lays foundation for such future investigations.
Conclusions
Collectively, our findings indicate that (i) evaluating
SOCS1 protein expression may have a prognostic signifi-
cance in PCa, however this requires development of
highly specific and sensitive clinical grade antibodies,
and (ii) MET and p21, which are partly regulated by
SOCS1, may also be useful in identifying aggressive can-
cers. Clearly, prospective studies in larger cohorts are
needed to evaluate these parameters as well as their cor-
relation to resistance to androgen ablation therapy,
serum biomarkers and distant metastasis in order to val-
idate their utility as prognostic markers and, possibly as
targets for personalized therapy.
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